Douglas Lankler Net Worth

The estimated Net Worth of Douglas M Lankler is at least $20.1 Миллион dollars as of 23 February 2024. Mr. Lankler owns over 95,755 units of Pfizer stock worth over $6,849,087 and over the last 12 years he sold PFE stock worth over $13,280,250. In addition, he makes $0 as Executive Vice President и General Counsel at Pfizer.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Lankler PFE stock SEC Form 4 insiders trading

Douglas has made over 30 trades of the Pfizer stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 95,755 units of PFE stock worth $2,617,942 on 23 February 2024.

The largest trade he's ever made was exercising 115,342 units of Pfizer stock on 23 February 2022 worth over $3,153,450. On average, Douglas trades about 16,553 units every 46 days since 2012. As of 23 February 2024 he still owns at least 230,920 units of Pfizer stock.

You can see the complete history of Mr. Lankler stock trades at the bottom of the page.

Douglas Lankler biography

Douglas M. Lankler serves as Executive Vice President, General Counsel of the Company. Executive Vice President, Chief Compliance and Risk Officer. Executive Vice President, Chief Compliance Officer. Senior Vice President and Chief Compliance. Senior Vice President, Deputy General Counsel and Chief Compliance Officer.

How old is Douglas Lankler?

Douglas Lankler is 54, he's been the Executive Vice President и General Counsel of Pfizer since 2014. There are 24 older and 5 younger executives at Pfizer. The oldest executive at Pfizer Inc. is Wyllie Don Cornwell, 72, who is the Independent Director.

What's Douglas Lankler's mailing address?

Douglas's mailing address filed with the SEC is 66 HUDSON BOULEVARD EAST, ATTN: CORPORATE SECRETARY, NEW YORK, NY, 10001-2192.

Insiders trading at Pfizer

Over the last 12 years, insiders at Pfizer have traded over $216,003,942 worth of Pfizer stock and bought 24,324 units worth $872,198 . The most active insiders traders include Shantanu Narayen, Ian C Read и James M Kilts. On average, Pfizer executives and independent directors trade stock every 12 days with the average trade being worth of $2,169,896. The most recent stock trade was executed by Jennifer B. Damico on 13 August 2024, trading 5,154 units of PFE stock currently worth $147,714.

What does Pfizer do?

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.

Complete history of Mr. Lankler stock trades at Pfizer

Pfizer executives and stock owners

Pfizer executives and other stock owners filed with the SEC include:

• Albert Bourla,
  Chairman of the Board, Chief Executive Officer
• Frank D'Amelio,
  Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
• Mikael Dolsten,
  Chief Scientific Officer, President - Worldwide Research, Development and Medical
• John Young,
  Chief Business Officer, Group President
• Dr. Albert Bourla D.V.M., DVM, Ph.D.,
  Chairman & CEO
• Frank A. D'Amelio,
  CFO & Exec. VP
• Dr. Mikael Dolsten M.D., Ph.D.,
  Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical
• Angela Hwang,
  Group Pres of Biopharmaceuticals Group
• John D. Young,
  Advisor
• Shantanu Narayen,
  Lead Independent Director
• Wyllie Don Cornwell,
  Independent Director
• Helen Hobbs,
  Independent Director
• Suzanne Nora Johnson,
  Independent Director
• Joseph Echevarria,
  Independent Director
• James Kilts,
  Independent Director
• Ronald Blaylock,
  Independent Director
• Dan Littman,
  Independent Director
• Scott Gottlieb,
  Independent Director
• James Quincey,
  Independent Director
• Susan Hockfield,
  Independent Director
• Susan Desmond-Hellmann,
  Director
• Gordon Loh,
  Senior Vice President, Corporate Audit
• Jennifer Damico,
  Senior Vice President, Principal Accounting Officer, Controller
• Sally Susman,
  Chief Corporate Affairs Officer, Executive Vice President
• Alexander Mackenzie,
  Executive Vice President, Chief Development Officer
• Douglas Lankler,
  Executive Vice President, General Counsel
• Rady Johnson,
  Chief Compliance, Quality and Risk Officer, Executive Vice President
• Lidia Fonseca,
  Executive Vice President, Chief Technology Officer and Digital Officer
• Dawn Rogers,
  Chief Human Resource Officer, Executive Vice President
• Angela Hwang,
  Group President, Pfizer Biopharmaceuticals Group
• Rady A. Johnson,
  Exec. VP and Chief Compliance, Quality & Risk Officer
• Douglas M. Lankler,
  Exec. VP & Gen. Counsel
• Christopher J. Stevo CFA,
  Sr. VP & Chief Investor Relations Officer
• Lidia L. Fonseca,
  Exec. VP and Chief Digital & Technology Officer
• Jennifer B. Damico,
  Sr. VP, Controller & Principal Accounting Officer
• Mike McDermott,
  Chief Financial Officer
• William Pao,
  Executive Vice President
• Stephen W Sanger,
  Director
• Frances D Fergusson,
  Director
• James C Smith,
  Director
• Laurie J Olson,
  Executive Vice President
• W Don Cornwell,
  Director
• Loretta V Cangialosi,
  Sr. Vice President, Controller
• Charles H Hill,
  Executive Vice President
• Dennis A Ausiello,
  Director
• Kirsten Lund Jurgensen,
  Executive Vice President
• Ian C Read,
  Chairman & CEO
• Freda C Lewis Hall,
  Executive Vice President
• Aamir Malik,
  Executive Vice President
• Christoffel Boshoff,
  Executive Vice President
• Michael Goettler,
  Group President
• Cyrus Taraporevala,
  Director
• Iii William H Gray,
  Director
• M Anthony Burns,
  Director
• Cavan M. Redmond,
  Group President
• Kristin C Peck,
  Executive Vice President
• David S Simmons,
  Business Unit President
• Geno J Germano,
  Business Unit President
• Anthony J Maddaluna,
  Executive Vice President
• Olivier Brandicourt,
  Business Unit President
• Marc Tessier Lavigne,
  Director
• George A Lorch,
  Director
• Amy W Schulman,
  Executive Vice President
• Constance J Horner,
  Director
• Payal Sahni,
  Executive Vice President
• William R Jr Carapezzi,
  Executive Vice President
• Michael Mc Dermott,
  Executive Vice President
• David M Denton,
  Chief Financial Officer & EVP